Spruce Biosciences Targets Q4 BLA for MPS IIIB Drug, Secures $5.5M Patient Advocacy Investment
SPRB has more than doubled off its 52-week low of $7 on light trading volume (0.4× avg).
Summary
Spruce Biosciences reported Q2 2026 results and outlined a clear path toward a BLA submission for TA-ERT in Q4 2026, seeking accelerated approval for MPS IIIB. The company also plans to initiate the required TrAnsform confirmatory study in Q4. A combined $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society will partially fund an expanded access program, broadening patient access. The appointment of Jessica Cohen Pfeffer as VP Clinical Development adds rare disease regulatory experience. With a market cap around $128M and a cash runway into Q2 2027, the BLA submission represents a potential transformative milestone for the company.
At the time of this announcement, SPRB was trading at $46.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.7M. The 52-week trading range was $7.00 to $240.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.